Valuation: Gentian Diagnostics

Market Cap 617M 65.51M 58.48M 53.81M 48.84M 92.55M 6.14B 94.85M 644M 257M 3.29B 246M 241M 10.35B P/E 2026 *
-798x
P/E 2027 * 15.3x
Enterprise Value 530M 56.27M 50.23M 46.22M 41.95M 79.5M 5.27B 81.47M 553M 220M 2.82B 211M 207M 8.89B EV / Sales 2026 *
2.68x
EV / Sales 2027 * 2.11x
Free-Float
49.96%
Yield 2026 *
2.01%
Yield 2027 * 2.51%
1 day+2.05%
1 week+4.18%
Current month+4.18%
1 month+3.64%
3 months-1.97%
6 months+3.37%
Current year-29.26%
1 week 37.6
Extreme 37.6
40.1
1 month 37.3
Extreme 37.3
43
Current year 33.5
Extreme 33.5
60
1 year 33.5
Extreme 33.5
60
3 years 33.5
Extreme 33.5
65.8
5 years 33.5
Extreme 33.5
75.2
10 years 22
Extreme 22
89
Manager TitleAgeSince
Chief Executive Officer - -
Chief Executive Officer 54 2024-04-28
Chief Tech/Sci/R&D Officer 69 2024-08-04
Director TitleAgeSince
Director/Board Member 62 -
Chairman 66 2024-04-28
Director/Board Member 65 -
Date Insider Type Main position Quantity % Market Cap. Importance
5/8/25 BuyCompany 101,848 0.6604%
4/7/25 Buy

Director

5,000 0.0324%
3/3/25 Sell

Director

1,228,502 7.9657%
Change 5-day change 1-year change 3-year change Capi.($)
+2.05%+4.18%-29.75%+0.25% 64M
+0.53%+0.32%-12.22%+18.13% 190B
+0.97%+3.53%+10.93%+46.65% 125B
-0.04%+6.17%-8.25%+20.27% 124B
-1.65%+3.42%-38.20%+9.54% 99.31B
+3.66%+2.34%-5.18%+75.67% 63.65B
+1.59%+8.38%+18.50%-7.32% 57.71B
+4.53%+5.21%-0.41%+68.75% 53.26B
+3.53%-11.54%-8.86%+50.02% 47.03B
-0.13%+3.59%+3.73%-7.44% 36.15B
Average +1.64%+4.76%-6.97%+27.45% 79.62B
Weighted average by Cap. +1.26%+5.55%-6.72%+28.72%

Financials

2026 *2027 *
Net sales 198M 21.03M 18.77M 17.27M 15.68M 29.71M 1.97B 30.45M 207M 82.36M 1.06B 78.93M 77.25M 3.32B 228M 24.22M 21.62M 19.89M 18.05M 34.21M 2.27B 35.06M 238M 94.84M 1.22B 90.89M 88.95M 3.83B
Net income -1M -106K -94.81K -87.24K -79.18K -150K -9.96M -154K -1.04M -416K -5.33M -399K -390K -16.79M 40M 4.25M 3.79M 3.49M 3.17M 6M 398M 6.15M 41.74M 16.64M 213M 15.95M 15.61M 671M
Net Debt -87M -9.24M -8.25M -7.59M -6.89M -13.05M -866M -13.38M -90.79M -36.19M -464M -34.68M -33.94M -1.46B -135M -14.34M -12.8M -11.78M -10.69M -20.26M -1.34B -20.76M -141M -56.15M -720M -53.82M -52.67M -2.27B
Projected Income Statement - Annual - Gentian Diagnostics
Logo Gentian Diagnostics
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Employees
64
Date Price Change Volume
26-11-09 NOK 39.90 +2.05% 51,354
26-11-06 NOK 39.10 +1.30% 168
26-11-05 NOK 38.60 -3.26% 13,865
26-11-04 NOK 39.90 +1.01% 4,000
26-11-03 NOK 39.50 -0.50% 1,096
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Gentian Diagnostics
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
39.10NOK
Average target price
60.00NOK
Spread / Average Target
+53.45%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Gentian Diagnostics
  1. Stock Market
  2. Stocks
  3. GENT Stock